Avion Pharma Renews Ongoing Partnership With Gnosis, S.P.A., To License Quatrefolic, Body-Ready Folate, Through Patent Life Of 2028
ATLANTA, Aug. 16, 2016 /PRNewswire/ -- Avion Pharmaceuticals, LLC, a specialty pharmaceutical company and maker of Prenate® prescription prenatal vitamins, recently announced it has solidified its continuing partnership with Gnosis S.P.A. to provide Quatrefolic®, the fourth-generation folate, as part of the Prenate® prescription prenatal vitamin portfolio. As a result of the recent agreement, Avion will provide Quatrefolic® through the duration of its patent life, which runs through 2028.
Quatrefolic® ((6S)-5 methyltetrahydrofolate glucosamine salt) is a patented and unique body-ready form of folate that is an important component of prenatal nutritional support for both expecting mothers or women trying to conceive. Folic acid helps prevent neural tube defects (NTD) such as spina bifida. Up to 50 percent of American women have MTHFR polymorphism, which does not allow the body to metabolize folic acid that is available through diet or nutritional supplements. 1,2 Quatrefolic® folate, available in all Prenate® prescription prenatals, is delivered in the form that is already in the biologically active form for the body to use and overcomes the MTHFR polymorphism common in women allowing all women, regardless of their genetic predisposition, to absorb folate and enjoy the protective benefits as they prepare for motherhood.
For more than 33 years, the Prenate® family of products has provided trusted prescription prenatal and postnatal nutritional support for both mom and baby based on expert recommendations. Quatrefolic® is now an important component of the Prenate® formulations because all women expecting or trying to conceive should have adequate folate intake prior to day 28 of pregnancy when the neural tube closes.
"Avion is proud to support our community of moms and babies with prescription nutritional support that meet the highest standards for pregnancy and breastfeeding," said Avion President Mike Sullivan. "This important partnership with Gnosis, S.P.A., allows Prenate® to demonstrate our commitment to both our prescribers and our women's healthcare communities with the gold standard in bioavailable folate".
About Avion Pharmaceuticals, LLC
Avion Pharmaceuticals, LLC is a specialty pharmaceutical company formed to develop and market a portfolio of innovative pharmaceutical products in the Women's Heath and Dermatology therapeutic areas. Avion Pharmaceuticals focuses on identifying opportunities to acquire and enhance the market potential of innovative, commercially available therapeutics and late-stage development drugs to fulfill unmet medical needs. For additional information about Avion Pharmaceuticals please contact the company at 678-325-5188. For more information about Prenate® Restore visit www.prenate.com.
Quatrefolic® is a registered trademark of Gnosis, SpA.
Covered by one or more claims of U.S. Patent # 7,947,662 CAS# 1181972-37-1
1.Czeizel AE, Dudás I, Paput L, Bánhidy F. Prevention of neural-tube defects with periconceptional folic acid, methylfolate, or multivitamins? Ann Nutr Metab. 2011; 58(4):263271. 2. Molloy A, Daly S, Mills J, et al. Thermolabile variant of 5,10-methylenetetrahydrofolate reductase associated with low red-cell folates: implications for folate intake recommendations. Lancet. 1997; 349:159193.
Logo - http://photos.prnewswire.com/prnh/20160407/352848LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/avion-pharmaceuticals-llc-renews-ongoing-partnership-with-gnosis-spa-to-license-quatrefolic-body-ready-folate-through-patent-life-of-2028-300313589.html
SOURCE Avion Pharmaceuticals, LLC
